

Gastric, Esophageal, and Gastroesophageal Junction Cancer (Adenocarcinoma) Pathways

Patient Name: _____

Date of Birth: _____

Member Number: _____

Treatment Start Date: _____

Pathology: _____

Stage: _____

Line of Therapy: __ Neoadjuvant/Pre-Op __ Adjuvant/Post-Op
__ 1st Line __ 2nd Line __ 3rd Line __ 3rd Line+

ECOG Performance Status: _____ **ICD-10 Code:** _____

Will the patient be undergoing surgery? __ Yes __ No

Will the patient be undergoing radiation therapy? __ Yes __ No

Primary Therapy | Resectable and Unresectable Disease

Cisplatin and fluorouracil (5FU)

Fluorouracil (5FU) and cisplatin (Platinol) with concurrent radiation therapy (RT)

FLOT: Fluorouracil (5FU), leucovorin, oxaliplatin, and docetaxel (Taxotere)

Paclitaxel (Taxol) and carboplatin (Paraplatin) with concurrent RT

Post-Operative Treatment

Fluorouracil (5FU) and leucovorin with concurrent radiation therapy (RT)

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Negative | First Line of Therapy (1st Line)

Cisplatin (Platinol) and fluorouracil (5FU)

Fluorouracil (5FU) and irinotecan (Camptosar)

FLO / FOLFOX: fluorouracil (5FU), leucovorin, and oxaliplatin (Eloxatin)

FLP: fluorouracil (5FU), leucovorin, and cisplatin (Platinol)

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | HER2 Positive | First Line of Therapy (1st Line)

Cisplatin (Platinol), fluorouracil (5FU), and trastuzumab (Herceptin)

Recurrent/Metastatic or Locally Advanced/Inoperable Disease | Second Line of Therapy (2nd Line)

Irinotecan (Camptosar)

Paclitaxel (Taxol)

Note: Pathway lists are solely for the purpose of eligibility for enhanced reimbursement and are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.

